Eledon Pharmaceuticals, Inc. (ELDN): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of ELDN were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Eledon Pharmaceuticals
From the latest filingsOverall: more buying than selling. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ELDN
161 funds and institutions reported ELDN shares worth $186M at the end of Q2 2026, about 62% of the company. The largest holder is Bvf Inc with 8.3%.
Funds and institutions (13F) 62%Everyone else 38%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Bvf Inc | 6.29M | 8.30% | $24.8M | No change |
| BlackRock, Inc. | 5.12M | 6.76% | $20.2M | +17% |
| Defilade Capital Management, L.P. | 3.53M | 4.65% | $13.9M | -1% |
| Vanguard Capital Management LLC | 3.42M | 4.51% | $13.5M | +4% |
| Goldman Sachs Group Inc | 2.51M | 3.31% | $9.9M | +578% |
| Ensign Peak Advisors, Inc | 2.10M | 2.77% | $8.3M | -15% |
| Geode Capital Management, LLC | 1.96M | 2.58% | $7.7M | +9% |
| Catalio Capital Management, LP | 1.70M | 2.23% | $6.7M | +3% |
| State Street Corp | 1.62M | 2.14% | $6.4M | +40% |
| Zimmer Partners, LP | 1.60M | 2.10% | $6.3M | -15% |
| Sphera Funds Management Ltd. | 1.19M | 1.57% | $4.7M | -33% |
| AWM Investment Company, Inc. | 1.10M | 1.45% | $4.3M | No change |
| UBS Group AG | 1.05M | 1.38% | $4.1M | +91% |
| Kingdon Capital Management, L.l.c. | 1.04M | 1.37% | $4.1M | No change |
| Millennium Management LLC | 979,712 | 1.29% | $3.9M | – |
| Bank of America Corp | 883,097 | 1.16% | $3.5M | +2% |
| ADAR1 Capital Management, LLC | 647,812 | 0.85% | $2.6M | -34% |
| 22nw, LP | 636,364 | 0.84% | $2.5M | No change |
| Northern Trust Corp | 616,399 | 0.81% | $2.4M | +13% |
| AQR Capital Management LLC | 581,028 | 0.77% | $2.3M | +237% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No ELDN insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ELDN short interest
High short interest. 10.2% of ELDN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.25M ELDN shares were sold short, 10.2% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 7.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.25M | 10.16% | +5% | 1.10M | 7.5 |
| Oct 15, 2026 | 7.90M | 9.72% | +1% | 770,159 | 10.2 |
| Sep 30, 2026 | 7.85M | 9.66% | -5% | 888,937 | 8.8 |
| Sep 15, 2026 | 8.26M | 10.16% | +7% | 919,103 | 9.0 |
| Aug 31, 2026 | 7.75M | 9.53% | +23% | 958,381 | 8.1 |
| Aug 14, 2026 | 6.29M | 7.74% | +1% | 915,083 | 6.9 |
| Jul 31, 2026 | 6.21M | 8.19% | +13% | 957,400 | 6.5 |
| Jul 15, 2026 | 5.52M | 7.28% | -29% | 1.43M | 3.9 |
| Jun 30, 2026 | 7.83M | 10.33% | +4% | 2.43M | 3.2 |
| Jun 15, 2026 | 7.50M | 9.89% | +3% | 1.01M | 7.5 |
| May 29, 2026 | 7.28M | 9.60% | +7% | 920,216 | 7.9 |
| May 15, 2026 | 6.78M | 8.94% | -10% | 1.27M | 5.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Eledon Pharmaceuticals company events
Eledon Pharmaceuticals filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 13, 2026.
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 22, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Jan 2, 2026SharesSold new shares outside a public offering. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Eledon Pharmaceuticals financials
Famous investors that hold ELDN
4 of the 50 well-known investors we track reported holding ELDN in their latest 13F filing. The largest position is Israel Englander's, worth $2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 789,861 | $2M | 0.0% | -19% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 556,900 | $1.4M | 0.0% | +177% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 53,247 | $135K | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 32,201 | $81.5K | 0.0% | -85% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ELDN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 7.0% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 7.0% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.9% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.9% |
Questions about Eledon Pharmaceuticals, Inc. (ELDN) stock
Who owns the most ELDN stock?
The largest reported owner of Eledon Pharmaceuticals, Inc. (ELDN) is Bvf Inc, with 8.3% of the company. In total, 161 funds and institutions reported holding ELDN at the end of Q2 2026, together about 62% of the shares. See the largest owners.
Are ELDN insiders buying or selling?
No ELDN insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in ELDN?
As of Oct 30, 2026, 8.25M ELDN shares were sold short, 10.2% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 7.5 trading days (days to cover). See the history.
Which famous investors hold ELDN?
4 of the 50 well-known investors we track reported ELDN in their latest 13F filing, including Israel Englander, Jim Simons, Steve Cohen. The largest position is worth $2M. See all holders.
Executive pay
Eledon Pharmaceuticals's chief executive was paid a total of $3.2M for the year ended Dec 31, 2025, down 43% from $5.6M the year before. In the last 12 months, Eledon Pharmaceuticals's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.